Background We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population. diagnosis of NHL. To give context to the survival pattern styles in incidence and mortality were also estimated. Results Compared with 1990-1994 after adjusting for… Continue reading Background We evaluated if the survival benefit of adding rituximab to